Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Core Insights - Alpha Tau Medical Ltd. is advancing its innovative alpha-radiation cancer therapy, Alpha DaRT, with ongoing patient treatments in a U.S. multi-center pilot study for pancreatic cancer [2][5] - The company has received a radioactive material license for its New Hampshire facility, which is a significant step towards commercial readiness [2][5] - Alpha Tau has a strong financial position with a cash balance of $75.9 million, allowing for continued clinical advancement and commercial preparation [2][11] Recent Corporate Highlights - The company reported a significant increase in patient treatment rates and interest from industry peers during the third quarter of 2025 [2] - Alpha Tau has invested nearly $2 million into its New Hampshire facility in Q3 2025 to prepare for operational readiness [2] - The first patient was treated in the U.S. multi-center pancreatic cancer clinical trial, which aims to enroll up to 30 patients [5] Expected Upcoming Milestone Targets - Completion of patient recruitment in the U.S. pivotal ReSTART trial for recurrent cutaneous squamous cell carcinoma is expected by Q1 2026 [5] - The company anticipates a response from Japan's PMDA regarding marketing authorization for Alpha DaRT in treating recurrent head and neck cancer by the end of 2025 [5] - The first patient in the U.S. GBM pilot study is expected to be treated in Q4 2025 [5] Financial Results - Research and Development expenses for the nine months ended September 30, 2025, were $22.5 million, an increase from $19.5 million in the same period in 2024 [6] - Marketing expenses decreased to $1.4 million in 2025 from $1.7 million in 2024 [7] - General and Administrative expenses rose to $5.8 million in 2025 from $4.6 million in 2024 [8] - The company reported a net loss of $30.5 million, or $0.39 per share, for the nine months ended September 30, 2025, compared to a net loss of $22.3 million, or $0.32 per share, in the same period in 2024 [10][20] Balance Sheet Highlights - As of September 30, 2025, the company had cash and cash equivalents totaling $75.9 million, an increase from $62.9 million at the end of 2024 [11] - Total assets were reported at $86.2 million as of September 30, 2025, compared to $104.7 million at the end of 2024 [16][18]